White label – Pompe disease - ClinicalTrials.eu

Study to Evaluate IOpener-Melanoma Test for Predicting Response to Immunotherapy in Stage III or IV Skin Melanoma Patients

Recruiting

3 1 1 1
Investigated Diseases:
- Malignant melanoma
Investigated Drugs:
- Nivolumab
- Pembrolizumab
Study on the Effects and Safety of Rilzabrutinib for Adults with Graves’ Disease

Recruiting

2 1 1
Investigated Diseases:
- Graves’ disease
Investigated Drugs:
- Rilzabrutinib
Reduced Immunosuppression Therapy Trial for Elderly Kidney Transplant Recipients with End-Stage Renal Disease

Recruiting

3 1 1 1
Investigated Diseases:
- End stage renal disease
Investigated Drugs:
Evaluation of Botulinum Toxin Injections for Women with Severe Primary Dysmenorrhea Unresponsive to First-Line Treatments

Recruiting

3 1 1
Investigated Drugs:
- Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Study on Sentinel Lymph Node Technique in Early-Stage Ovarian Cancer Using Pertechnetate (99mTc) Sodium, Human Serum Albumin, and Indocyanine Green

Recruiting

3 1 1 1
Investigated Drugs:
Evaluating Citrulline, Folic Acid, Vericiguat, and Tadalafil Combination for Patients with Treatment-Resistant High Blood Pressure

Recruiting

2 1 1 1
Investigated Diseases:
- Hypertension
Investigated Drugs:
Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

Recruiting

2 1 1
Investigated Diseases:
- Neoplasm
Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

Recruiting

2 1 1 1
Investigated Diseases:
- Uveal melanoma
Investigated Drugs:
- Tebentafusp
Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

Recruiting

3 1
Investigated Drugs:
- Paltusotine
+4
Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Recruiting

3 1 1
Investigated Diseases:
- Acute myeloid leukaemia
Investigated Drugs:
+6

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies